Birdwatch Note
2023-12-12 02:03:59 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
The approval is based on positive clinical data from several ARCT-154 studies, including an ongoing 16,000 subject efficacy study performed in Vietnam as well as a Phase 3 COVID-19 booster trial. https://biomelbourne.org/japans-ministry-of-health-labour-and-welfare-approves-csl-and-arcturus-therapeutics-arct-154-the-first-self-amplifying-mrna-vaccine-approved-for-covid-in-adults/
Written by 337667AAE38F8EA20823A5FFD051684AAEC0A794E4F0FE0F21453F3BE1FDFF7B
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1734359937793618406
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1734393629538722131
- noteId - 1734393629538722131
- participantId -
- noteAuthorParticipantId - 337667AAE38F8EA20823A5FFD051684AAEC0A794E4F0FE0F21453F3BE1FDFF7B Participant Details
- createdAtMillis - 1702346639414
- tweetId - 1734359937793618406
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- The approval is based on positive clinical data from several ARCT-154 studies, including an ongoing 16,000 subject efficacy study performed in Vietnam as well as a Phase 3 COVID-19 booster trial. https://biomelbourne.org/japans-ministry-of-health-labour-and-welfare-approves-csl-and-arcturus-therapeutics-arct-154-the-first-self-amplifying-mrna-vaccine-approved-for-covid-in-adults/
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2023-12-12 02:03:59 UTC (1702346639414) |
2023-12-12 06:44:53 UTC (1702363493722) |
CURRENTLY_RATED_HELPFUL | 2023-12-13 03:28:16 UTC (1702438096692) |
NEEDS_MORE_RATINGS | 2023-12-12 06:44:53 UTC (1702363493722) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
| rated at | rated by | |
| 2023-12-12 16:08:20 -0600 | Rating Details | |
| 2023-12-12 15:35:14 -0600 | Rating Details | |
| 2023-12-12 15:09:16 -0600 | Rating Details | |
| 2023-12-12 13:47:07 -0600 | Rating Details | |
| 2023-12-12 07:39:56 -0600 | Rating Details | |
| 2023-12-12 07:12:23 -0600 | Rating Details | |
| 2023-12-12 06:41:37 -0600 | Rating Details | |
| 2023-12-12 01:23:25 -0600 | Rating Details | |
| 2023-12-12 00:47:03 -0600 | Rating Details | |
| 2023-12-11 22:44:04 -0600 | Rating Details | |
| 2023-12-11 22:26:35 -0600 | Rating Details | |
| 2023-12-11 22:12:44 -0600 | Rating Details | |
| 2023-12-11 21:50:10 -0600 | Rating Details | |
| 2023-12-11 21:22:37 -0600 | Rating Details | |
| 2023-12-11 20:57:48 -0600 | Rating Details | |
| 2023-12-11 20:29:58 -0600 | Rating Details | |
| 2023-12-11 20:19:19 -0600 | Rating Details | |
| 2023-12-11 20:17:48 -0600 | Rating Details | |
| 2023-12-11 20:10:03 -0600 | Rating Details | |
| 2023-12-11 20:09:41 -0600 | Rating Details | |
| 2023-12-11 20:06:18 -0600 | Rating Details | |
| 2023-12-11 20:05:36 -0600 | Rating Details | |
| 2023-12-13 11:51:12 -0600 | Rating Details | |
| 2023-12-13 07:37:06 -0600 | Rating Details | |
| 2023-12-13 04:41:46 -0600 | Rating Details | |
| 2023-12-12 05:08:17 -0600 | Rating Details | |
| 2023-12-16 03:24:57 -0600 | Rating Details | |
| 2023-12-16 00:22:47 -0600 | Rating Details | |
| 2023-12-17 00:27:06 -0600 | Rating Details | |
| 2023-12-12 05:53:51 -0600 | Rating Details | |
| 2024-01-19 09:21:13 -0600 | Rating Details |